Fallopian Tube Cancer Market - Size, Share, Outlook, and Forecast till 2026

Fallopian Tubes also called as uterine tube are pair of tubes, which carry an egg from the ovary to the uterus. Fallopian tube cancer also called as tubal cancer is caused due to uncontrolled growth of cells in fallopian tubes that connect the ovaries and the uterus. This is very rare type of cancer and it is characterized by symptoms such as abnormal vaginal bleeding, especially after menopause, abdominal pain or a feeling of pressure in the abdomen, abnormal vaginal discharge that is white, clear or pinkish, and pelvic mass at the time of diagnosis. Although fallopian tube cancer can occur at any age, it majorly affects women between the ages of 50 and 60, age. Also, it is more common in Caucasian women who had few or no children.

Increasing prevalence of gynecological and reproductive disorders such as breast cancer, endometrial cancer, cervical cancer, ovarian cancer, and vaginal cancer is key factor fueling growth of the fallopian tube cancer market. Previous research studies reported that women who have inherited the gene linked to breast and ovarian cancer, called BRCA1, are show an increased risk of developing fallopian tube cancer. According to the article published in the University of California San Francisco, fallopian tube cancer is rare and accounts for 2 percent of all gynecologic cancers. Around 1,500 to 2,000 cases of fallopian tube cancer have been reported worldwide. An estimated 300 to 400 women are diagnosed with the condition annually in the U.S.

Key Developments in Fallopian Tube Cancer Market

Market players are engaged in developing novel drugs for treatment of fallopian tube cancer in order to meet increasing demand from healthcare sector, which in turn is driving growth of the fallopian tube cancer market size. Furthermore, launch and novel drugs to treat the fallopian cancer and their approval by regulatory bodies is boosting growth of the fallopian tube cancer market. For instance, in June 2018, the Genentech, biotechnology company received Food and Drug Administration (FDA) approval for combination of Avastin (bevacizumab) plus the chemotherapy agents carboplatin and paclitaxel, followed by Avastin alone, for the treatment of patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer following initial surgical resection. Key players operating in fallopian tube cancer market include AbbVie Inc, Amgen Inc, Arrien Pharmaceuticals LLC, AstraZeneca Plc., Atara Biotherapeutics Inc, Bayer AG, BeiGene Ltd, Boehringer Ingelheim GmbH, Boston Biomedical Inc, Bristol-Myers Squibb Co, Caladrius Biosciences Inc, Celgene Corp, Celldex Therapeutics Inc, Dr. Reddy’s Laboratories Ltd, Eisai Co Ltd, Eli Lilly and Co, EpiThany Inc, Exelixis Inc, F. Hoffmann-La Roche Ltd among others.

About WMR

Worldwide Market Reports is your one-stop repository of detailed and in-depth market research reports compiled by an extensive list of publishers from across the globe. We offer reports across virtually all domains and an exhaustive list of sub-domains under the sun. The in-depth market analysis by some of the most vastly experienced analysts provide our diverse range of clients from across all industries with vital decision making insights to plan and align their market strategies in line with current market trends. Worldwide Market Research’s well-researched inputs that encompass domains ranging from IT to healthcare enable our prized clients to capitalize upon key growth opportunities and shield against credible threats prevalent in the market in the current scenario and those expected in the near future.

1001 4th Ave,
#3200
Seattle, WA 98154,
U.S

This release was published on openPR.